IL301291A - ניסוחים פמטרקס - Google Patents

ניסוחים פמטרקס

Info

Publication number
IL301291A
IL301291A IL301291A IL30129123A IL301291A IL 301291 A IL301291 A IL 301291A IL 301291 A IL301291 A IL 301291A IL 30129123 A IL30129123 A IL 30129123A IL 301291 A IL301291 A IL 301291A
Authority
IL
Israel
Prior art keywords
pemetrexed
pharmaceutical composition
storage
concentration
months
Prior art date
Application number
IL301291A
Other languages
English (en)
Inventor
Feng-Jing Chen
Steven L Krill
Original Assignee
Eagle Pharmaceuticals Inc
Chen feng jing
Steven L Krill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc, Chen feng jing, Steven L Krill filed Critical Eagle Pharmaceuticals Inc
Publication of IL301291A publication Critical patent/IL301291A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL301291A 2016-02-19 2016-02-19 ניסוחים פמטרקס IL301291A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/018703 WO2017142556A1 (en) 2016-02-19 2016-02-19 Pemetrexed formulations

Publications (1)

Publication Number Publication Date
IL301291A true IL301291A (he) 2023-05-01

Family

ID=59625349

Family Applications (5)

Application Number Title Priority Date Filing Date
IL301291A IL301291A (he) 2016-02-19 2016-02-19 ניסוחים פמטרקס
IL261179A IL261179B (he) 2016-02-19 2018-08-15 פורמולציות של פמטרקסד
IL290647A IL290647B2 (he) 2016-02-19 2022-02-15 ניסוחים פמטרקס
IL312427A IL312427B1 (he) 2016-02-19 2024-04-25 פורמולציות פמטרקסד
IL324306A IL324306A (he) 2016-02-19 2025-10-28 פורמולציות פמטרקסד

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL261179A IL261179B (he) 2016-02-19 2018-08-15 פורמולציות של פמטרקסד
IL290647A IL290647B2 (he) 2016-02-19 2022-02-15 ניסוחים פמטרקס
IL312427A IL312427B1 (he) 2016-02-19 2024-04-25 פורמולציות פמטרקסד
IL324306A IL324306A (he) 2016-02-19 2025-10-28 פורמולציות פמטרקסד

Country Status (9)

Country Link
EP (1) EP3416646A4 (he)
JP (1) JP2019505561A (he)
KR (2) KR102794126B1 (he)
CN (1) CN109152778B (he)
AU (3) AU2016393213B2 (he)
CA (1) CA3014755C (he)
IL (5) IL301291A (he)
MX (2) MX2022009547A (he)
WO (1) WO2017142556A1 (he)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
DE602007011384D1 (de) * 2006-08-14 2011-02-03 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
US9655898B2 (en) * 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
IN2012DE00912A (he) * 2012-03-27 2015-09-11 Fresenius Kabi Oncology Ltd
EP2666463A1 (en) * 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
EP2854768B2 (en) * 2012-05-30 2025-06-18 Fresenius Kabi Oncology Limited Pharmaceutical compositions of pemetrexed
WO2013179310A1 (en) * 2012-05-31 2013-12-05 Mylan Laboratories Limited Stable aqueous compositions of pemetrexed
JP6099557B2 (ja) * 2013-12-27 2017-03-22 富士フイルム株式会社 注射液製剤及びその製造方法
KR101703980B1 (ko) * 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
WO2015193517A2 (en) * 2014-10-16 2015-12-23 Synthon B.V. Liquid pharmaceutical composition comprising pemetrexed

Also Published As

Publication number Publication date
CN109152778B (zh) 2021-08-10
IL290647A (he) 2022-04-01
AU2023202089A1 (en) 2023-06-01
AU2023202089B2 (en) 2025-05-29
CA3014755A1 (en) 2017-08-24
AU2016393213B2 (en) 2022-03-31
IL261179A (he) 2018-10-31
IL290647B1 (he) 2023-04-01
WO2017142556A1 (en) 2017-08-24
MX2022009547A (es) 2022-09-09
AU2025223868A1 (en) 2025-09-18
IL312427A (he) 2024-06-01
IL261179B (he) 2022-03-01
KR20240049356A (ko) 2024-04-16
KR102794126B1 (ko) 2025-04-11
IL290647B2 (he) 2023-08-01
IL324306A (he) 2025-12-01
MX2018010037A (es) 2019-07-04
CA3014755C (en) 2023-11-14
EP3416646A4 (en) 2019-09-04
KR20180132643A (ko) 2018-12-12
EP3416646A1 (en) 2018-12-26
IL312427B1 (he) 2025-12-01
AU2016393213A1 (en) 2018-10-04
CN109152778A (zh) 2019-01-04
JP2019505561A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
US9572887B2 (en) Formulations of bendamustine
JP2016521731A (ja) 抗がん剤を含む安定な水溶性医薬組成物
WO2017002030A1 (en) Stable liquid formulations of melphalan
EP3008064B1 (en) Stable pemetrexed arginine salt and compositions comprising it
US12115164B2 (en) Pemetrexed formulations
US20190151234A1 (en) Stable liquid pharmaceutical formulations of bendamustine
IL290647B2 (he) ניסוחים פמטרקס
JP7543365B2 (ja) ペメトレキセド製剤
US20190070136A1 (en) Parenteral compositions of carmustine
WO2017037232A1 (en) Anidulafungin formulations
WO2019130228A1 (en) Stable liquid compositions of melphalan
WO2024009319A1 (en) Liquid injectable compositions of trilaciclib
WO2025165852A1 (en) Liquid formulations of lurbinectedin
US20090062295A1 (en) Pharmaceutical Products